Type of evidence	Key findings	Level of evidence (USPSTF ranking*)	Citation(s)
Clinical guidelines	 The NHLBI suggests the following routine clinical laboratory evaluations for children with SCD: Complete blood count with white blood count differential, every 3 months for children ages 3 to 24 months and every 6 months for children ages 2 years and over. Reticulocyte count every 3 months for children ages 3 to 24 months and every 6 months for children ages 3 to 24 months and every 6 months for children ages 3 to 24 months and every 6 months for children ages 3 to 24 months and every 6 months for children ages 3 to 24 months and every 6 months for children ages 2 and over. Pulmonary function (transcutaneous O₂ saturation), every 6 months for children over 1 year of age. (NHLBI, pg. 26) 		National Heart, Lung and Blood Institute. The Management of Sickle Cell Disease. National Institutes of Health. Bethesda, MD, 2002.
Clinical guidelines	 The AAP sections on Hematology/Oncology and the Committee on Genetics suggest the following: Obtain baseline complete blood and reticulocyte counts during the first year of life. For children ages 1-5 years, document baseline complete blood and reticulocyte counts (every 6–12 months for patients with HbSS and S beta zero thalassemia and at least yearly for patients with HbSC and S beta plus thalassemia) For children ages 5-18 years, document baseline complete blood and reticulocyte counts at least yearly. 	II	American Academy of Pediatrics Section on Hematology/Oncology and Committee on Genetics. Health supervision for children with sickle cell disease. Pediatrics. Mar 2002;109(3):526-535.
Descriptive study	 Pulse oximetry provides a safe, noninvasive, accurate way to measure arterial hemoglobin [oxygen] saturation in patients with SCD who are prone to decreased oxygen states (hypoxemia) caused by hemoglobin S. 	111	Fitzgerald RK, Johnson A. Pulse oximetry in sickle cell anemia. <i>Crit Care Med</i> . Sep 2001;29(9):1803-1806.

Table 5: Evidence Supporting Outpatient Blood Testing in Children with Sickle Cell Disease

Note: USPSTF criteria for assessing evidence at the individual study level are as follows: I) Properly powered and conducted randomized controlled trial (RCT); well-conducted systematic review or meta-analysis of homogeneous RCTs. II) Well-designed cohort or case-control analytic study. III) Opinions of respected authorities, based on clinical experience; descriptive studies or case reports; reports of expert committees.